{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:18:57Z","timestamp":1773339537459,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"DOI":"10.7759\/cureus.105083","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:21:28Z","timestamp":1773303688000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Saroglitazar in Patients With Metabolic Disease in India Stratified by Estimated Glomerular Filtration Rate (eGFR): A Retrospective, Observational, Electronic Medical Record (EMR)-Based Real-World Evidence Study"],"prefix":"10.7759","author":[{"given":"Kamlakar","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deodatta","family":"Chafekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganapathi","family":"Bantwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supratik","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Golay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanmugraj","family":"G.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinodhini","family":"Mudaliyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal S","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanthy","family":"G.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garima","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2019.12.001","article-title":"Metabolic syndrome: the Indian public health perspective","volume":"76","author":"Bhalwar R","year":"2020","unstructured":"Bhalwar R. Metabolic syndrome: the Indian public health perspective. Med J Armed Forces India. 2020, 76:8-16. 10.1016\/j.mjafi.2019.12.001","journal-title":"Med J Armed Forces India"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2016.12.004","article-title":"The metabolic syndrome and chronic kidney disease","volume":"183","author":"Zhang X","year":"2017","unstructured":"Zhang X, Lerman LO. The metabolic syndrome and chronic kidney disease. Transl Res. 2017, 183:14-25. 10.1016\/j.trsl.2016.12.004","journal-title":"Transl Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109924","article-title":"Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals","volume":"188","author":"Noubiap JJ","year":"2022","unstructured":"Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, et al.. Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract. 2022, 188:109924. 10.1016\/j.diabres.2022.109924","journal-title":"Diabetes Res Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240971","article-title":"Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis","volume":"15","author":"Krishnamoorthy Y","year":"2020","unstructured":"Krishnamoorthy Y, Rajaa S, Murali S, Rehman T, Sahoo J, Kar SS. Prevalence of metabolic syndrome among adult population in India: a systematic review and meta-analysis. PLoS One. 2020, 15:e0240971. 10.1371\/journal.pone.0240971","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework","volume":"15","author":"Theodorakis N","year":"2025","unstructured":"Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025, 15:213. 10.3390\/biom15020213","journal-title":"Biomolecules"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85813","article-title":"Cardiovascular-renal-hepatic-metabolic syndrome: interlinked pathophysiology and integrated management approach","volume":"17","author":"Arragan Lezama CA","year":"2025","unstructured":"Arragan Lezama CA, Jaramillo Ramos JJ, Armas Eguiz\u00e1bal DA, Solares Ovando XS, Minera Villagr\u00e1n JC, Males Caiza CJ. Cardiovascular-renal-hepatic-metabolic syndrome: interlinked pathophysiology and integrated management approach. Cureus. 2025, 17:e85813. 10.7759\/cureus.85813","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01738-3","article-title":"Advancing cardiovascular, kidney, and metabolic medicine: a narrative review of insights and innovations for the future","volume":"16","author":"Fernando K","year":"2025","unstructured":"Fernando K, Connolly D, Darcy E, Evans M, Hinchliffe W, Holmes P, Strain WD. Advancing cardiovascular, kidney, and metabolic medicine: a narrative review of insights and innovations for the future. Diabetes Ther. 2025, 16:1155-76. 10.1007\/s13300-025-01738-3","journal-title":"Diabetes Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.12.021","article-title":"The prevention and management of chronic kidney disease among patients with metabolic syndrome","volume":"107","author":"Zhu D","year":"2025","unstructured":"Zhu D, Judge PK, Wanner C, Haynes R, Herrington WG. The prevention and management of chronic kidney disease among patients with metabolic syndrome. Kidney Int. 2025, 107:816-24. 10.1016\/j.kint.2024.12.021","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113450","article-title":"Association of metabolic syndrome with decreased glomerular filtration rate among 75,468 Chinese adults: a cross-sectional study","volume":"9","author":"Song H","year":"2014","unstructured":"Song H, Wang X, Cai Q, Ding W, Huang S, Zhuo L. Association of metabolic syndrome with decreased glomerular filtration rate among 75,468 Chinese adults: a cross-sectional study. PLoS One. 2014, 9:e113450. 10.1371\/journal.pone.0113450","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.012","article-title":"Metabolic syndrome but not obesity measures are risk factors for accelerated age-related glomerular filtration rate decline in the general population","volume":"93","author":"Stefansson VT","year":"2018","unstructured":"Stefansson VT, Schei J, Solbu MD, Jenssen TG, Melsom T, Eriksen BO. Metabolic syndrome but not obesity measures are risk factors for accelerated age-related glomerular filtration rate decline in the general population. Kidney Int. 2018, 93:1183-90. 10.1016\/j.kint.2017.11.012","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.05.012","article-title":"Association between metabolic syndrome and chronic kidney disease in a Chinese urban population","volume":"470","author":"Chen J","year":"2017","unstructured":"Chen J, Kong X, Jia X, Li W, Wang Z, Cui M, Xu D. Association between metabolic syndrome and chronic kidney disease in a Chinese urban population. Clin Chim Acta. 2017, 470:103-8. 10.1016\/j.cca.2017.05.012","journal-title":"Clin Chim Acta"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurpra.2017.04.017","article-title":"Guidelines for chronic kidney disease: defining, staging, and managing in primary care","volume":"13","author":"McManus MS","year":"2017","unstructured":"McManus MS, Hopman WM, Bartholomew C, Lee T, Darbyson C. Guidelines for chronic kidney disease: defining, staging, and managing in primary care. J Nurse Pract. 2017, 13:400-10. 10.1016\/j.nurpra.2017.04.017","journal-title":"J Nurse Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155912","article-title":"Deciphering the molecular pathways of saroglitazar: a dual PPAR \u03b1\/\u03b3 agonist for managing metabolic NAFLD","volume":"155","author":"Ezhilarasan D","year":"2024","unstructured":"Ezhilarasan D. Deciphering the molecular pathways of saroglitazar: a dual PPAR \u03b1\/\u03b3 agonist for managing metabolic NAFLD. Metabolism. 2024, 155:155912. 10.1016\/j.metabol.2024.155912","journal-title":"Metabolism"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269531","article-title":"Efficacy and safety of saroglitazar for the management of dyslipidemia: a systematic review and meta-analysis of interventional studies","volume":"17","author":"Chhabra M","year":"2022","unstructured":"Chhabra M, Vidyasagar K, Gudi SK, Sharma J, Sharma R, Rashid M. Efficacy and safety of saroglitazar for the management of dyslipidemia: a systematic review and meta-analysis of interventional studies. PLoS One. 2022, 17:e0269531. 10.1371\/journal.pone.0269531","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89028","article-title":"Evaluation of effectiveness and tolerability of saroglitazar in metabolic disease patients of India: a retrospective, observational, electronic medical record-based real-world evidence study","volume":"17","author":"Das S","year":"2025","unstructured":"Das S, Gupta S, Lathia T, et al.. Evaluation of effectiveness and tolerability of saroglitazar in metabolic disease patients of India: a retrospective, observational, electronic medical record-based real-world evidence study. Cureus. 2025, 17:e89028. 10.7759\/cureus.89028","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.07.014","article-title":"Exploring the nexus: the place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum","volume":"127","author":"Kanbay M","year":"2024","unstructured":"Kanbay M, Guldan M, Ozbek L, Copur S, Covic AS, Covic A. Exploring the nexus: the place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum. Eur J Intern Med. 2024, 127:1-14. 10.1016\/j.ejim.2024.07.014","journal-title":"Eur J Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S353305","article-title":"Metabolic syndrome components and chronic kidney disease in a community population aged 40 years and older in Southern China: a cross-sectional study","volume":"15","author":"Xiao H","year":"2022","unstructured":"Xiao H, Shao X, Gao P, Zou H, Zhang X. Metabolic syndrome components and chronic kidney disease in a community population aged 40 years and older in Southern China: a cross-sectional study. Diabetes Metab Syndr Obes. 2022, 15:839-48. 10.2147\/DMSO.S353305","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw231","article-title":"Metabolic risk factors in nondiabetic adolescents with glomerular hyperfiltration","volume":"32","author":"Lee AM","year":"2017","unstructured":"Lee AM, Charlton JR, Carmody JB, Gurka MJ, DeBoer MD. Metabolic risk factors in nondiabetic adolescents with glomerular hyperfiltration. Nephrol Dial Transplant. 2017, 32:1517-24. 10.1093\/ndt\/gfw231","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-008-0074-3","article-title":"Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) study","volume":"46","author":"Monami M","year":"2009","unstructured":"Monami M, Pala L, Bardini G, et al.. Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) study. Acta Diabetol. 2009, 46:191-6. 10.1007\/s00592-008-0074-3","journal-title":"Acta Diabetol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2013.08.004","article-title":"The number of metabolic syndrome components is a good risk indicator for both early- and late-stage kidney damage","volume":"24","author":"Okada R","year":"2014","unstructured":"Okada R, Yasuda Y, Tsushita K, Wakai K, Hamajima N, Matsuo S. The number of metabolic syndrome components is a good risk indicator for both early- and late-stage kidney damage. Nutr Metab Cardiovasc Dis. 2014, 24:277-85. 10.1016\/j.numecd.2013.08.004","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100233","article-title":"Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial","volume":"63","author":"Rodriguez-Gutierrez R","year":"2022","unstructured":"Rodriguez-Gutierrez R, Gonz\u00e1lez JG, Parmar D, Shaikh F, Cruz-L\u00f3pez P. Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial. J Lipid Res. 2022, 63:100233. 10.1016\/j.jlr.2022.100233","journal-title":"J Lipid Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55466-3","article-title":"Effect of a dual PPAR \u03b1\/\u03b3 agonist on insulin sensitivity in patients of type 2 diabetes with hypertriglyceridemia: a randomized double-blind placebo-controlled trial","volume":"9","author":"Jain N","year":"2019","unstructured":"Jain N, Bhansali S, Kurpad AV, et al.. Effect of a dual PPAR \u03b1\/\u03b3 agonist on insulin sensitivity in patients of type 2 diabetes with hypertriglyceridemia: a randomized double-blind placebo-controlled trial. Sci Rep. 2019, 9:19017. 10.1038\/s41598-019-55466-3","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9065","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra A","year":"2020","unstructured":"Mitra A. An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Cureus. 2020, 12:e9065. 10.7759\/cureus.9065","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"Pai V","year":"2014","unstructured":"Pai V, Paneerselvam A, Mukhopadhyay S, et al.. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014, 8:132-41. 10.1177\/1932296813518680","journal-title":"J Diabetes Sci Technol"},{"key":"ref25","article-title":"Study of saroglitazar in treatment of pre-diabetes with dyslipidemia: STOP-D","volume":"66","author":"Bhosle D","year":"2018","unstructured":"Bhosle D, Bhosle V, Bobde J, Bhagat A, Shaikh H, Kadam R. Study of saroglitazar in treatment of pre-diabetes with dyslipidemia: STOP-D. J Assoc Physicians India. 2018, 66:14-7.","journal-title":"J Assoc Physicians India"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"Gawrieh S","year":"2019","unstructured":"Gawrieh S, Wilson LA, Cummings OW, et al.. Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels. Am J Gastroenterol. 2019, 114:1626-35. 10.14309\/ajg.0000000000000388","journal-title":"Am J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal O","year":"2020","unstructured":"Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020, 10:21117. 10.1038\/s41598-020-78342-x","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay S","year":"2023","unstructured":"Bandyopadhyay S, Samajdar SS, Das S. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2023, 47:102174. 10.1016\/j.clinre.2023.102174","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy159","article-title":"Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials","volume":"34","author":"Idzerda NM","year":"2019","unstructured":"Idzerda NM, Pena MJ, Parving HH, de Zeeuw D, Heerspink HJ. Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrol Dial Transplant. 2019, 34:1699-706. 10.1093\/ndt\/gfy159","journal-title":"Nephrol Dial Transplant"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04164-6","article-title":"Risk factors associated with Indian type 2 diabetes patients with chronic kidney disease: CITE study, a cross-sectional, real-world, observational study","volume":"26","author":"Kumar A","year":"2025","unstructured":"Kumar A, Mazumdar A, Bhattacharjee AK, et al.. Risk factors associated with Indian type 2 diabetes patients with chronic kidney disease: CITE study, a cross-sectional, real-world, observational study. BMC Nephrol. 2025, 26:245. 10.1186\/s12882-025-04164-6","journal-title":"BMC Nephrol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0253","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI)","volume":"16","author":"Jani RH","year":"2014","unstructured":"Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Joshi S. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014, 16:63-71. 10.1089\/dia.2013.0253","journal-title":"Diabetes Technol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/460628-effectiveness-and-safety-of-saroglitazar-in-patients-with-metabolic-disease-in-india-stratified-by-estimated-glomerular-filtration-rate-egfr-a-retrospective-observational-electronic-medical-record-emr-based-real-world-evidence-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:21:29Z","timestamp":1773303689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/460628-effectiveness-and-safety-of-saroglitazar-in-patients-with-metabolic-disease-in-india-stratified-by-estimated-glomerular-filtration-rate-egfr-a-retrospective-observational-electronic-medical-record-emr-based-real-world-evidence-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.105083","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}